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Summary
QUESTIONS UNDER STUDY AND PRINCIPLES: Es-
timating glomerular filtration rate (GFR) in hospitalised
patients with chronic kidney disease (CKD) is important
for drug prescription but it remains a difficult task. The pur-
pose of this study was to investigate the reliability of se-
lected algorithms based on serum creatinine, cystatin C and
beta-trace protein to estimate GFR and the potential added
advantage of measuring muscle mass by bioimpedance.
METHODS: In a prospective unselected group of patients
hospitalised in a general internal medicine ward with CKD,
GFR was evaluated using inulin clearance as the gold
standard and the algorithms of Cockcroft, MDRD, Larsson
(cystatin C), White (beta-trace) and MacDonald (creatinine
and muscle mass by bioimpedance).
RESULTS: 69 patients were included in the study. Median
age (interquartile range) was 80 years (73–83); weight 74.7
kg (67.0–85.6), appendicular lean mass 19.1 kg
(14.9–22.3), serum creatinine 126 μmol/l (100–149),
cystatin C 1.45 mg/l (1.19–1.90), beta-trace protein 1.17
mg/l (0.99–1.53) and GFR measured by inulin 30.9 ml/
min (22.0–43.3). The errors in the estimation of GFR and
the area under the ROC curves (95% confidence interval)
relative to inulin were respectively: Cockcroft 14.3 ml/
min (5.55–23.2) and 0.68 (0.55–0.81), MDRD 16.3 ml/
min (6.4–27.5) and 0.76 (0.64–0.87), Larsson 12.8 ml/min
(4.50–25.3) and 0.82 (0.72–0.92), White 17.6 ml/min
(11.5–31.5) and 0.75 (0.63–0.87), MacDonald 32.2 ml/min
(13.9‒45.4) and 0.65 (0.52‒0.78).
CONCLUSIONS: Currently used algorithms overestimate
GFR in hospitalised patients with CKD. As a consequence
eGFR targeted prescriptions of renal-cleared drugs, might
expose patients to overdosing. The best results were ob-
tained with the Larsson algorithm. The determination of
muscle mass by bioimpedance did not provide significant
contributions.
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Introduction
Glomerular filtration rate (GFR) can be measured using
standardised methods such as the determination of inulin
clearance or by calculating the clearance of alternative sub-
strates, such as iodinated contrast agents (for instance, io-
hexol) or radioisotopes [1]. In clinical practice, however,
determination of GFR by these methods is so cumbersome
and costly that clinicians cannot use them on a regular basis
and must be satisfied with an estimation of GFR calcu-
lated from endogenous markers of kidney function, tradi-
tionally serum creatinine and, more recently, cystatin C and
beta-trace protein. The determination of creatinine is re-
producible, not expensive and easily accessible. However,
the use of creatinine for measuring kidney function has a
number of limitations, specifically owing to the fraction of
the substance eliminated by non-renal routes and to its de-
pendence on muscle mass and, last but not least, on diet-
ary intake [2–11]. Cystatin C and beta-trace protein do of-
fer some theoretical advantages, the main one being their
low susceptibility to anthropometric variables [12–20];
however, they have failed to win a place in the delicate
compromise between determination cost, accuracy and re-
producibility despite the fact that they have now been avail-
able for a number of years [21–24]. Also owing to limited
intra-individual variability, creatinine thus continues to be
the endogenous substrate of first choice for estimating kid-
ney function and, when appropriate, for determining the
stage of dysfunction [25, 26].
Starting from creatinine it is possible to estimate either,
GFR by a number of formulas, the most popular of which
is the one obtained by Levey in 1999 from the Modification
of Diet in Renal Disease (MDRD) study data [4, 5] or cre-
atinine clearance with the equation published by Cockcroft
in 1976 [3]. Because of the fraction eliminated by tubu-
lar and intestinal routes, creatinine clearance usually over-
estimates GFR; however, the difference between the two
measurements falls within determination-related error dis-
persion [27]. For the purpose of correcting the error given
by the difference between individual muscle mass and av-
erage muscle mass by age group [28, 29], MacDonald pro-
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posed in 2006 an equation that also included determination
of appendicular lean mass by bioelectrical impedance ana-
lysis [30, 31].
There are also dedicated equations available for estimating
GFR from cystatin C and beta-trace protein (proposed by
Larsson in 2004 [13] and by White in 2007, respectively
[20]), that are not or little affected by body composition
[12–20] but are unfortunately exposed to great intra- and
inter-individual variability just like the substrates they are
based on [21–24].
Despite progress in knowledge about endogenous markers
of kidney function, the determination of GFR remains diffi-
cult. The difficulty is further enhanced in patients at the ex-
tremes of the normal distribution, particularly with regard
to weight, muscle mass, and age [2, 7, 32].
The frail elderly who are admitted to internal medicine
wards, with their many comorbidities and the consequences
of their disabilities, often have complex conditions treated
with medications having a narrow therapeutic spectrum
and, by definition, they put the equations used for estim-
ating kidney function to the hardest of tests. This is even
more so when we know that one third to one fourth of all
patients above 60 years of age, some of whom with normal
creatinine values, have at least stage III chronic kidney dis-
ease (CKD) [33] and that GFR has been shown to decrease
by 0.8 ml/min/year on average, starting from the age of 40
[2].
Confused by the number and diversity of available equa-
tions, and anxious to verify their accuracy in the elderly
population of our internal medicine wards with CKD and
moderately compromised kidney function, we decided to
compare the main equations (Cockcroft [3], MDRD [5],
White [20], Larsson [13] and MacDonald [30]), using in-
ulin clearance as the gold standard [34, 35].
Materials and methods
Patients and measurements
We recruited 70 unselected Caucasian patients with CKD
and moderate kidney function impairment (stage III–IV ac-
cording to KDOQI guidelines [25]) among the elderly pop-
ulation (>70 year old) of the internal medicine wards of two
secondary care hospitals in the south of Switzerland (Re-
gional Hospitals of Locarno and Bellinzona). Every patient
had to be cardiopulmonary compensated showing a stable
weight at least in the 4 days before inclusion. We excluded
patients with evidence of unstable renal function in the last
two weeks (serum creatinine excursions >20 µmol/l), be-
fore inclusion.
To minimise bias, starting on kick-off day, all patients
meeting the selection criteria were asked to participate in
the study and every patient from whom an informed con-
sent was obtained was recruited.
On the inclusion day, blood samples were obtained from
each patient to determine serum creatinine, cystatin C and
beta-trace protein additionally bioimpedance was assessed.
On the same day the glomerular filtration rate (GFR) was
measured using a single bolus inulin clearance [36].
Blood samples were rapidly (waiting time <15 minutes)
centrifuged for 10 minutes (1,500 RPM) in the local labor-
atory. Plasma and serum were extracted and frozen at re-
spectively –80 and –20 °C and then sent to the “Central
Chemical and Immunology Laboratory of the Public Hos-
pital Network of Bellinzona” to determine the serum creat-
inine, Cystatin C and beta-trace protein and to the “Neph-
rology Research Laboratory of the Lausanne University
Hospital” to determine the plasma inulin.
Laboratory assessments for serum creatinine, cystatin
C and beta-trace protein and for plasma inulin
To obtain the serum creatinine value, a modified IDMS cal-
ibrated kinetic Jaffé reaction on a Hitachi 912 photometer
was used. Serum cystatin C and beta trace-protein levels
were analysed with the Siemens method using the Behring
Nephelometer II.
Figure 1
Box Plot showing the absolute error in estimating GFR (inulin
clearence as the gold standard). CYSA, BTPA, CKCA, MDRDA,
ALMA = absolute error in estimating the GFR using algorithms
based respectively on Cystatin C; Beta-trace protein, creatinine and
anthropometric values (Cockcroft); creatinine and anthropometric
values (MDRD), creatinine, anthropometric values and
appendicular lean mass (approximating muscle mass) measured by
bioimpedance.
Figure 2
Scatterplots comparing the estimations obtained with the tested
algorithms to the GFR measured by inulin; the diagonal line
indicates the equality. A Passing and Bablok analysis shows the
trend of the distribution and its 95% confidence intervals.
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR
estimated by Beta Trace Protein; GFR ALM = GFR estimated by
Appendicular Lean Mass and creatinine. GFR CKC= GFR
estimated by Cockcroft’s algorithm. GFR MDRD = GFR estimated
by MDRD (Modification of Diet in Renal Disease) algorithm.
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Plasma inulin was determined using a spectrophotometer
(microadaptation of an anthrone procedure on a Technicon
Autoanalyser [37]).
Inulin clearance
Inulin clearance has been used as the gold standard for
the determination of GFR [39, 40]. Considering (1.) the
known good correlation between the clearance values ob-
tained with a constant infusion of inulin and with a single
shot method respectively and (2.) the simplicity of the short
infusion strategy, the latter was used to determine the GFR
[35, 36].
Two timed blood samples after the bolus injection of inulin
could have been enough to calculate the GFR [36]; we de-
cided however to increase the number of blood samples to
4 in order to set up a better disappearance curve and to es-
timate the inulin clearance (one-compartment model) thrice
for every patient according to the following formula.
GFR Inulin = (ln Cn‒1 ‒ ln Cn)/(tn‒1 ‒ tn)
(C = inulin concentration [mg/l]; t = time [min])
Concerning the inulin administration; on the study day, at
time 0, a bolus of 12.5 ml of Inutest® (a solution contain-
ing 25% inulin) was administered intravenously over 10
minutes. Altogether five blood samples were obtained; the
first one prior to inulin administration and then at 90, 180,
270 and 360 minutes.
GFR and creatinine clearance estimation
To estimate creatinine clearance and GFR, the algorithms
of Cockcroft (CCL CKC) and Levey (GFR MDRD) based
on serum creatinine and anthropometric values, Larsson
based on cystatin C (GFR CYS), White based on serum
Figure 3
ROC Curves plotting the sensitivity against 1 minus the specificity
of the selected algorithms in predicting an inulin clearance <30 ml/
min.
CYS = GFR estimated by Cystatin C; BTP = GFR estimated by
Beta Trace Protein; ALM = GFR estimated by Appendicular Lean
Mass and creatinine. CKC= GFR estimated by Cockcroft’s
algorithm. MDRD = GFR estimated by MDRD (Modification of Diet
in Renal Disease) algorithm. The ideal test would have an AUC of
1, whereas a random guess would have an AUC of 0.5.
creatinine and beta-trace protein (GFR BTP) and MacDon-
ald based on serum creatinine, anthropometric values and
the appendicular lean mass obtained by bio-impedance
(proportional to muscular mass) (GFR ALM) were used
(table 1).
Cystatin C and Beta Trace Protein
Cystatin C is an endogenous, 13 kilo-Dalton protein, gen-
erated at a relatively constant rate, freely filtered by the
glomeruli and reabsorbed and catabolised by the tubular
epithelial cells [12, 13].
Similarly, Beta Trace Protein is a low molecular weight
glycoprotein, primarily isolated as prostaglandin D2 syn-
thase, in its turn filtered by the glomeruli and with minimal
extra-renal elimination [19, 20].
Predicting appendicular lean mass by bioimpedance
The appendicular lean mass was estimated by bioimped-
ance; a commonly used method for estimating body com-
position based on the study of the passive electrical proper-
ties of the biological tissues. Bio-impedance allows estim-
ating the relative volumes of different tissues or fluids in
the body as total body water, appendicular lean mass (ap-
proximating the muscle mass) and fat body weight.
The efficacy and the reproducibility of the bioimpedance
in estimating the body composition has been evaluated and
judged favorably in many studies [38–40].
To perform the measurements electrodes were put on the
dorsal surfaces of the ipsilateral wrist and ankle (on the
metacarpal- and metatarsal phalangeal joint of the hand and
foot) and a BIA 101 device (Akern, Florence, Italy) was
used. Then, on the basis of the resulting resistance (Rz) and
reactance (Xc), using the Bodygram® software, the appen-
dicular lean mass (ALM) was calculated.
Statistical and data analysis
Statistical and data analysis were performed using the
SPSS 20.0 and the Analyse-it 2.26 statistical software
packages. Considering that the absolute error in predicting
GFR is not normally distributed we decided to analyse the
significance using a Friedman Test. In all cases a p ≤0.05
was considered statistically significant. Distributions were
graphically depicted using box-plots and scatterplots.
The quality of the measurements of the inulin clearances
was assessed analysing the intra-patient dispersion of the
GFR values calculated as the median of the difference
between the extremes.
To compare the accuracy of the selected prediction al-
gorithms we used: a Bland and Altman analysis in which
the error is plotted against the mean of measured and es-
timated GFR [41], a Passing and Bablok analysis depicting
graphycally the trend and 95% confidence intervals of the
distribution and receiver operating characteristic curves
(ROC) which give a graphical display of sensitivity and
specificity of the test. In ROC curves the sensitivity is plot-
ted versus 1 – specificity, with each point of the curve rep-
resenting a different cut-off level. The area under the curve
(AUC) describes the test overall performance; to facilitate
comparisons between individual variables the value was
given with the 95% confidence interval.
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Ethical approval was obtained from the local Ethics Com-
mittee (Comitato Etico Cantonale, Bellinzona), and all par-
ticipants gave written informed consent prior to enrolment.
Results
From the 70 recruited patients, one was excluded for in-
complete blood samples.
The demographic and clinical characteristics of the study
group are presented in table 2. As a comparison, the mean
age and eGFR (MDRD) of the totality of the patients ad-
mitted to the internal medicine wards of the two hospitals
in the study year (N = 5,676) was (median and interquartile
range) 76 (66–84) years and 57 (38–81) ml/min respect-
ively. Patients with chronic kidney disease stage III‒IV
represented 52.9% of the entire population.
Figure 4
Bland and Altman analysis. In this analysis the differences between
the gold standard and the selected prediction algorithm, are plotted
against the mean of measured and calculated GFR for each
individual patient.
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR
estimated by Beta Trace Protein; GFR ALM = GFR estimated by
Appendicular Lean Mass and creatinine. GFR CKC= GFR
estimated by Cockcroft’s algorithm. GFR MDRD = GFR estimated
by MDRD (Modification of Diet in Renal Disease) algorithm.
The GFR measured with inulin and calculated with the se-
lected algorithms and the absolute error in performing the
estimation (median and mean values to allow a quantitative
comparison) are listed in table 3. The reliability of the in-
ulin clearance was assessed analysing the intra-patient ab-
solute difference between the extremes of the three indi-
vidual determinations (median, 25% and 75% interquartile
ranges which were: 8.2, 3.6 and 13.6 ml/min respectively).
All selected algorithms significantly overestimate GFR in
our group of patients (p <0.001).
The absolute error in estimating GFR is depicted graphic-
ally in figure 1. The difference among the median values
of the selected algorithms was found to be significant (p
<0.001). The estimations obtained on the basis of cystatin
C were characterised by the lowest median and mean error
(table 3), while those obtained with the McDonald al-
gorithm were the worst. Outliers 45 and 46 were character-
ised by a large body weight and estimated muscular mass
(118 and 98, and 40 and 35 kg respectively).
The distribution of the values obtained estimating GFR
with the 5 tested algorithms, compared to the reference
method (inulin clearance) is depicted graphically using
scatterplots in figure 2. A Passing and Bablok analysis
shows the trend of the distribution and its 95% confidence
intervals compared to the identity line.
The ROC curves comparing sensitivity and specificity of
the tested algorithms in predicting an inulin clearance <30
ml/min are depicted in figure 3. The area under the curves
and the 95% confidence intervals were respectively: CKC
0.68 (0.55–0.81), MDRD 0.76 (0.64–0.87), Cystatin C 0.82
(0.72–0.92), BTP 0.75 (0.63–0.87), ALM 0.65 (0.52–0.78).
The Bland and Altman analysis is shown in figure 4.
The percentage of patients wrongly attributed on the basis
of the selected prediction algorithm, to a lower or a higher
CKD stage is summarised in table 4. GFR CYS, inducing
less class changes compared to the other algorithms, ob-
tained the better score followed in order by GFR CKC,
GFR MDRD, GFR BTP and GFR ALM.
Table 1: Selected estimation algorithms. Formula used to estimate the Creatinine Clearance and the GFR respectively.
GFR or CCl (ml/min) Algorithm
CCL CKC (140 ‒ age [year]) × weight [kg] / (creatinine [μmol/l] × 72) × (0.85 if female)
GFR MDRD 175 × (creatinine [μmol/l])‒1.154 × (age [year])‒0.203 × (0.742 if female)
GFR CYS 77.239 × Cystatin C (mg/l)‒1.2623
GFR BTP 167.8 × BTP [mg/l]‒0.758 × creatinine [μmol/l]‒0.204 × (0.871 if female)
GFR ALM 101.008‒1.014 × LOG10 (creatinine [μmol/l] / 88) + 0.01644 × ALM [kg] + 0.07108 ×√ weight (Kg)
CCL CKC = creatinine clearance estimated by the Cockcroft algorithm; GFR MDRD = GFR estimated by the MDRD (Modification of Diet in Renal Disease) algorithm; GFR
CYS = GFR estimated on the basis of the cystatin C value; GFR BTP = GFR estimated on the basis of the creatinine and the beta-trace protein value; GFR ALM = GFR
estimated on the basis of the creatinine and the appendicular lean mass.
Table 2: Clinical characteristics of the studied population (n = 69).
Median (25–75% interquartile range) Mean ± SD
Age (years) 80 (73–83) 78 ± 7
Weight (kg) 74.7 (67.0–85.6) 77.3 ± 15.2
BMI (kg/m2) 26.0 (23.3–30.0) 27.3 ± 5.2
ALM (kg) 19.1 (14.9–22.3) 19.1 ± 6.1
Creatinine (μmol/l) 126 (100–149) 134 ± 62
Cystatin C (mg/l) 1.45 (1.19–1.90) 1.71 ± 0.87
Beta-trace protein (mg/l) 1.17 (0.99–1.53) 1.34 ± 0.64
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Discussion
In this study, we compared 5 different equations designed
to estimate kidney function, based on serum creatinine
(Cockcroft [3] and MDRD [5]), cystatin C (Larsson [13]),
creatinine combined with beta-trace protein (White [20]),
and creatinine adjusted for muscle mass obtained by bio-
electrical impedance analysis (MacDonald [30]), respect-
ively. Inulin clearance measured by the single shot method
was taken as the gold standard [34–36]. The population un-
der study, entirely of European Caucasian ethnicity, was
chosen amongst the inpatients admitted to the internal
medicine wards of two secondary care hospitals in southern
Switzerland. The only criteria for their selection were, an
age of >70 years and a chronic compromised kidney func-
tion based on MDRD eGFR (CKD stages III–IV).
As suggested by previous studies [2, 32], all tested equa-
tions are on average significantly overestimating kidney
function (+11.8 ml/min Cockcroft, +12.4 ml/min cystatin
C, +14.1 ml/min MDRD, +19.5 ml/min beta-trace protein,
+32.9 ml/min creatinine and muscle mass). In this respect,
a considerable number of patients would have changed
their KDOQI CKD severity classification by adjusting
GFR for the results of inulin clearance: 49% in the estim-
ation based on cystatin C, 56% by MDRD, 52% by Cock-
croft, 65% by beta-trace protein and 75% by creatinine and
muscle mass (table 4).
The inaccuracy of equations in this inpatient population
with extreme characteristics related to old age and poly-
morbidity is not surprising and has been previously repor-
ted [32].
However, considering how some criticalities attributed to
creatinine relate to the difficulty in estimating muscle mass,
we would have expected a better result from the MacDon-
ald formula, obtained by adjusting creatinine for body com-
position data measured by bioelectrical impedance ana-
lysis. Value dispersion was quite similar to that of other
equations or actually even worse (see error dispersion in
box plots, ROC curves and Bland-Altman analysis; figures
1, 3 and 4 respectively). We therefore had to conclude that
the determination of muscle mass by bioelectrical imped-
ance analysis did not result in any significant added contri-
bution in estimating GFR in the population under study.
However, taking into consideration the sound theoretical
context in favour of the definition and use of such an equa-
tion, we wondered why the MacDonald formula proved to
be imprecise. The small size of the population used to de-
termine it, the lack of external validation [30], the extreme
characteristics of the group which we tested, the possible
loss of precision in the analysis of body composition in
polymorbid elderly patients [42] and the use of a differ-
ent software to determine body composition, could all have
contributed to increased error dispersion.
The use of bioelectrical impedance analysis to reduce error
in creatinine-related GFR estimation, still retains a theoret-
ical attractiveness, and will have to be reassessed in studies
based on a wider population representative of the in-hospit-
al one, for which the interest in using a predictive equation
is greater.
The second surprise was to observe that the MDRD for-
mula did not offer significant advantages compared to
Cockcroft and seems to be less effective when compared
with the Larsson one.
The relative imprecision of the MDRD formula might be
related to the selected population (American in MDRD and
European in Cockcroft and Larsson) or, once again, to the
clinical characteristics of the population such as advanced
age and polymorbidities of the group in which we per-
formed the evaluation.
The results of the present study once again suggest that the
equations obtained from large clinical studies thus show
fragility in the extremes – in this case, advanced age and
polymorbidities [38]. This is particularly relevant as the
group selected for the study (CKD stages III-IV based on
Table 3: Measured versus estimated GFR. GFR measured with inulin and calculated with the selected algorithms and absolute error in performing the estimation. Data are
given using non-parametric and parametric values to allow a quantitative comparison; mean and SD values of the absolute error correlate with accuracy and precision
respectively.
Median (25–75% interquartile
range) ml/min
Mean ± SD
ml/min
Median error (25–75% interquartile
range) ml/min
Mean error ± SD
ml/min
GFR Inulin 30.9 (22.0–43.3) 34.9 ± 20.0
GFR CKC 45.1 (34.6–55.3) 46.7 ± 18.5 14.3 (5.55–23.2) 11.8 ± 19.2
GFR CYS 45.9 (31.9–59.4) 47.2 ± 23.0 12.8 (4.50–25.3) 12.4 ± 20.6
GFR BTP 54.2 (42.2–62.4) 54.4 ± 18.2 17.6 (11.5–31.5) 19.5 ± 17.7
GFR MDRD 47.9 (39.5–60.1) 49.0 ± 15.9 16.3 (6.4–27.5) 14.1 ± 19.8
GFR ALM 66.0 (46.3–77.7) 32.9 ± 27.2 32.2 (13.9–45.4) 32.9 ± 27.2
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular Lean Mass and creatinine.
GFR CKC = GFR estimated by Cockcroft’s algorithm. GFR MDRD = GFR estimated by MDRD (Modification of Diet in Renal Disease) algorithm.
Table 4: Percentage of KDOQI CKD class change [25] obtained correcting the results of the estimations with the gold standard (GFR Inulin).
KDOQI Class change GFR BTP GFR MDRD GFRALM GRFR CYS GFR CKC
Total class change % 65.3 56.5 75.5 49.3 52.3
+1 class 50.7 46.4 37.7 39.1 37.7
–1 class 1.5 7.2 0 1.5 5.8
+2 classes 11.6 2.9 31.9 7.2 5.8
–2 classes 1.5 0 1.5 1.5 1.5
± >2 classes 0 0 4.4 0 1.5
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular Lean Mass and creatinine.
GFR CKC= GFR estimated by Cockcroft’s algorithm. GFR MDRD = GFR estimated by MDRD (Modification of Diet in Renal Disease) algorithm.
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eGFR MDRD) accounts for 53% of the patients admitted
to the internal medicine wards of our hospitals.
Beta-trace protein does not seem to offer specific advant-
ages against creatinine and cystatin C; while the White
equation is the only one that does not generate outliers. Un-
fortunately this latter shows a greater error dispersion in
GFR estimation than Cockcroft, Larsson and MDRD.
What are we supposed to do in the face of such a large
margin of error? Assuming that the results were not gen-
erated by a bias related to the small group of patients ana-
lysed or to the single shot method used to measure in-
ulin clearance (see intra-patient dispersion of the GFR de-
termination in the results section); all the equations tested
seem to be prone to considerably overestimate GFR. While
we can imagine using the ones offering the best perform-
ance, we are not safe from either, the risk of intoxicating
patients with medications eliminated mainly by the renal
route characterised by a narrow therapeutic margin (e.g.,
some chemotherapics and antibiotics), and in a smaller
subgroup, the risk of being, on the contrary, below the
therapeutic range. Considering the relevance of the topic
and the amount of in-hospital patients matching the se-
lection criteria of the study, further investigation aimed to
confirm and more extensively characterising patients with
large GFR estimation errors, should be performed.
Therefore, it is of the utmost importance to closely monitor
the onset of any toxicity signs; whenever serum concentra-
tions of a medication used cannot be measured and to be
ready to adjust its dose or, when necessary, to replace the
drug with an alternative one. One important issue in elderly
patients is the correction of GFR to a standard body surface
area (1.73 m2) as for example in the MDRD formula. Pa-
tients in the extremes of weight do often not have a normal
body surface area and in that case drug overdosing may oc-
cur as well. In this respect the Cockcroft formula, consid-
ering also the weight, could be the safest.
In conclusion, the Cockcroft, Larsson, MDRD, White and
MacDonald equations are significantly overestimating kid-
ney function in our CKD stage III–IV inpatient population
(average overestimation ranging from 11.4 to 32.9 ml/min;
the extremes being Cockcroft and Macdonald respect-
ively). These results are important because the selected
population represents at least half of all patients admitted
in an internal medicine ward.
The best performance was obtained with the Larsson equa-
tion, based on cystatin C. The measurement by bioelectric-
al impedance analysis of muscle mass, introduced with cre-
atinine in the MacDonald formula, does not allow more
accurate results to be obtained, at least in our population of
patients.
Clinicians must therefore use estimated GFR with
prudence, being ready to discontinue medications with nar-
row therapeutic margins eliminated by the renal route in
all cases of suspected toxicity. New studies designed to im-
prove predictive equations to be used in elderly in-hospital
populations should be conducted.
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Figures (large format)
Figure 1
Box Plot showing the absolute error in estimating GFR (inulin clearence as the gold standard). CYSA, BTPA, CKCA, MDRDA, ALMA = absolute
error in estimating the GFR using algorithms based respectively on Cystatin C; Beta-trace protein, creatinine and anthropometric values
(Cockcroft); creatinine and anthropometric values (MDRD), creatinine, anthropometric values and appendicular lean mass (approximating
muscle mass) measured by bioimpedance.
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Figure 2
Scatterplots comparing the estimations obtained with the tested algorithms to the GFR measured by inulin; the diagonal line indicates the
equality. A Passing and Bablok analysis shows the trend of the distribution and its 95% confidence intervals.
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular
Lean Mass and creatinine. GFR CKC= GFR estimated by Cockcroft’s algorithm. GFR MDRD = GFR estimated by MDRD (Modification of Diet in
Renal Disease) algorithm.
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Figure 3
ROC Curves plotting the sensitivity against 1 minus the specificity of the selected algorithms in predicting an inulin clearance <30 ml/min.
CYS = GFR estimated by Cystatin C; BTP = GFR estimated by Beta Trace Protein; ALM = GFR estimated by Appendicular Lean Mass and
creatinine. CKC= GFR estimated by Cockcroft’s algorithm. MDRD = GFR estimated by MDRD (Modification of Diet in Renal Disease) algorithm.
The ideal test would have an AUC of 1, whereas a random guess would have an AUC of 0.5.
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Figure 4
Bland and Altman analysis. In this analysis the differences between the gold standard and the selected prediction algorithm, are plotted against
the mean of measured and calculated GFR for each individual patient.
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular
Lean Mass and creatinine. GFR CKC= GFR estimated by Cockcroft’s algorithm. GFR MDRD = GFR estimated by MDRD (Modification of Diet in
Renal Disease) algorithm.
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